Founded in 2024, with a current fund size of 66M USD, we are a prominent life sciences venture capital working closely with industry innovators to create cutting-edge medications and technologies.

Our primary focus is on developing inventive therapeutics that meet unfulfilled medical needs.

We adopt a proactive stance in identifying teams focused on developing impactful treatments, aiding in crafting efficient development strategies to make these therapies accessible to patients.

By assisting companies in accessing the capital market, our objective is to cultivate a mutually beneficial ecosystem that fosters investment growth and propels innovative therapeutics.

If you have any questions or inquiries, please contact us.

Email：ir@beileybiofund.com